Germline Polymorphisms Associated With the PSA Response in Men With Metastatic Prostate Cancer Treated With Androgen Deprivation Therapy
- To test the association between serum PSA response (< 4 ng/mL) at 7 months with
inherited variability of germline single nucleotide polymorphisms, in a set of
candidate genes, in patients with metastatic prostate cancer treated with combination
induction androgen-deprivation therapy comprising bicalutamide and goserelin.
OUTLINE: DNA extracted from whole blood or serum samples is analyzed for inherited
variability of germline single nucleotide polymorphisms.
Serum PSA values at 7 months
Kathleen A. Cooney, MD
University of Michigan Cancer Center